First Trust Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$55.4M Sell
353,224
-13,335
-4% -$2M 0.03% 579
2026
Q1
$56M Sell
366,559
-5,202
-1% -$797K 0.04% 535
2025
Q4
$51.3M Sell
371,761
-83,242
-18% -$10.9M 0.04% 552
2025
Q3
$58.3M Buy
455,003
+35,969
+9% +$4.39M 0.04% 508
2025
Q2
$50.7M Sell
419,034
-35,429
-8% -$3.99M 0.04% 534
2025
Q1
$50.7M Sell
454,463
-108,024
-19% -$11.5M 0.04% 532
2024
Q4
$54.7M Buy
562,487
+49,752
+10% +$5.31M 0.05% 476
2024
Q3
$59M Buy
512,735
+45,219
+10% +$5.13M 0.06% 432
2024
Q2
$49.8M Sell
467,516
-161,731
-26% -$16.2M 0.05% 477
2024
Q1
$60.9M Sell
629,247
-49,427
-7% -$5.07M 0.06% 414
2023
Q4
$68.5M Buy
678,674
+7,870
+1% +$760K 0.07% 344
2023
Q3
$68.3M Sell
670,804
-40,081
-6% -$4.07M 0.08% 329
2023
Q2
$71.7M Sell
710,885
-95,432
-12% -$9.54M 0.08% 353
2023
Q1
$74.2M Buy
806,317
+12,937
+2% +$1.13M 0.09% 340
2022
Q4
$72M Sell
793,380
-88,494
-10% -$7.45M 0.09% 363
2022
Q3
$67M Buy
881,874
+160,685
+22% +$13.3M 0.09% 340
2022
Q2
$61M Buy
721,189
+9,893
+1% +$868K 0.08% 401
2022
Q1
$62.4M Buy
711,296
+2,198
+0.3% +$190K 0.06% 444
2021
Q4
$62M Sell
709,098
-3,184
-0.4% -$264K 0.06% 448
2021
Q3
$58.3M Buy
712,282
+87,184
+14% +$7.84M 0.06% 423
2021
Q2
$57M Sell
625,098
-45,660
-7% -$4.07M 0.06% 439
2021
Q1
$57.3M Buy
670,758
+63,426
+10% +$5.69M 0.07% 410
2020
Q4
$57.4M Buy
607,332
+22,184
+4% +$1.94M 0.08% 363
2020
Q3
$50.9M Buy
585,148
+74,890
+15% +$6.49M 0.08% 362
2020
Q2
$44.6M Buy
510,258
+34,565
+7% +$2.98M 0.08% 376
2020
Q1
$39.2M Sell
475,693
-40,826
-8% -$3.64M 0.09% 370
2019
Q4
$48.9M Buy
516,519
+18,559
+4% +$1.67M 0.08% 370
2019
Q3
$43.3M Buy
497,960
+124,154
+33% +$11.1M 0.08% 354
2019
Q2
$34.1M Buy
373,806
+366,968
+5,367% +$31.1M 0.06% 397
2019
Q1
$589K Sell
6,838
-308,549
-98% -$24.8M ﹤0.01% 2073
2018
Q4
$24.3M Buy
315,387
+6,865
+2% +$534K 0.06% 435
2018
Q3
$23.8M Sell
308,522
-37,023
-11% -$2.74M 0.04% 546
2018
Q2
$23.4M Buy
345,545
+53,142
+18% +$3.67M 0.05% 500
2018
Q1
$21.2M Sell
292,403
-2,771
-0.9% -$211K 0.05% 528
2017
Q4
$22.2M Buy
295,174
+35,790
+14% +$2.7M 0.05% 507
2017
Q3
$20M Sell
259,384
-1,141
-0.4% -$86.2K 0.05% 522
2017
Q2
$19.5M Sell
260,525
-9,371
-3% -$664K 0.05% 512
2017
Q1
$18M Buy
269,896
+38,655
+17% +$2.58M 0.05% 546
2016
Q4
$15.1M Buy
231,241
+53,798
+30% +$3.49M 0.04% 581
2016
Q3
$12.6M Buy
177,443
+22,424
+14% +$1.63M 0.04% 641
2016
Q2
$11.5M Sell
155,019
-19,632
-11% -$1.36M 0.04% 645
2016
Q1
$11.3M Sell
174,651
-31,678
-15% -$2.16M 0.04% 610
2015
Q4
$15.9M Buy
206,329
+24,798
+14% +$1.97M 0.04% 498
2015
Q3
$15M Buy
181,531
+25,035
+16% +$2.23M 0.04% 482
2015
Q2
$13.8M Buy
156,496
+67,667
+76% +$6.21M 0.04% 617
2015
Q1
$7.85M Buy
88,829
+79
+0.1% +$7.01K 0.02% 841
2014
Q4
$7.37M Buy
88,750
+14,421
+19% +$1.2M 0.02% 860
2014
Q3
$6.27M Buy
74,329
+5,639
+8% +$456K 0.02% 915
2014
Q2
$5.57M Sell
68,690
-4,254
-6% -$335K 0.02% 941
2014
Q1
$5.56M Sell
72,944
-1,249
-2% -$91K 0.02% 921
2013
Q4
$5.34M Sell
74,193
-1,688
-2% -$117K 0.03% 926
2013
Q3
$5.22M Buy
75,881
+430
+0.6% +$28.4K 0.03% 859
2013
Q2
$4.78M Buy
+75,451
New +$4.91M 0.03% 787

Other funds holding NVS

First Trust Advisors's NVS Position: Q2 2026 in Review

First Trust Advisors reduced its Novartis (NVS) stake by 3.6% in Q2 2026, selling an estimated $2M and leaving 353,224 shares worth $55.4M. The position accounts for 0.03% of the portfolio, ranked #579.

First Trust Advisors first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $74.2M in Q1 2023. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • First Trust Advisors held 353,224 shares of Novartis worth $55.4M as of Q2 2026.
  • First Trust Advisors sold 13,335 Novartis shares in Q2 2026, an estimated $2M.
  • Novartis made up 0.03% of First Trust Advisors's portfolio in Q2 2026, its #579 holding.
  • First Trust Advisors first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • First Trust Advisors's Novartis position peaked at $74.2M in Q1 2023.
  • 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.